BRIEF published on 11/14/2024 at 19:05, 1 year ago ABIONYX Pharma : Bilan financier du troisième trimestre 2024 Chiffre D'affaires Biotechnologie Trésorerie ABIONYX Pharma T3 2024
BRIEF published on 11/14/2024 at 19:05, 1 year ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 1 year ago Information financière trimestrielle / Information financière du troisième trimestre ABIONYX Pharma communique son chiffre d'affaires et sa trésorerie du 3ème trimestre 2024. Retransmission de l'AGE le 28 novembre 2024 Chiffre D'affaires Trésorerie ABIONYX Pharma 3ème Trimestre 2024 Retransmission AGE
PRESS RELEASE published on 11/14/2024 at 19:00, 1 year ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
BRIEF published on 10/24/2024 at 19:35, 1 year 1 month ago ABIONYX Pharma présente les résultats de l'étude RACERS ABIONYX Pharma CER-001 Brain-fog Neuro-inflammation Kidney Week
BRIEF published on 10/24/2024 at 19:35, 1 year 1 month ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 1 month ago Informations privilégiées / Autres communiqués ABIONYX Pharma présente les résultats cliniques de l'étude RACERS sur le brouillard cérébral et l'efficacité de CER-001 au congrès annuel 2024 de l'ASN. Nouvelles données sur la neuro-inflammation et les troubles cognitifs ASN ABIONYX Pharma CER-001 Brain-fog Étude RACERS
PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 1 month ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 1 year 1 month ago ABIONYX Pharma reçoit un avis favorable de l'EMA pour le CER-001 ABIONYX Pharma CER-001 EMA Déficience LCAT AMM
BRIEF published on 10/21/2024 at 20:05, 1 year 1 month ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
Published on 12/05/2025 at 19:50, 24 minutes ago Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 54 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 29 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 54 minutes ago NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 2 hours 14 minutes ago SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 18:58, 1 hour 16 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 1 hour 59 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 2 hours 28 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 2 hours 56 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 56 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 3 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 3 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 6 hours 16 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
